Synageva BioPharma™ Reports Third Quarter 2013 Financial Results

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, today reported third quarter 2013 financial results and provided other business updates.

Synageva announces the hiring of Gregory A. Grabowski, M.D., FACMG

Gregory A. Grabowski, M.D. joins Synageva as a distinguished physician and accomplished researcher in the field of rare, genetic diseases. In his role at Synageva, Dr. Grabowski will assist in evaluating, designing, and implementing strategies to advance Synageva’s earlier stage pipeline programs.

“I am delighted to join Synageva at this exciting stage of the company’s evolution,” said Dr. Grabowski. “Joining Synageva represents a significant opportunity for me to support the company’s goals for patients with rare diseases and to extend my life’s dedication to developing life-changing therapies for patients suffering from these devastating diseases.”

“Dr. Grabowski is a leading authority in genetic and lysosomal storage diseases, including Gaucher and Fabry disease, and was an early pioneer in understanding LAL Deficiency,” said Anthony Quinn, MBChB, Ph.D., FRCP, Senior Vice President and Chief Medical Officer and Head of R&D of Synageva. “On behalf of the company, I welcome Greg to our team. We look forward to his contribution that will help us deliver on our commitment to advancing our pipeline programs and making a meaningful impact on the lives of patients.”

Prior to joining Synageva, Dr. Grabowski was most recently Director of the Division of Human Genetics at the Cincinnati Children’s Hospital Research Foundation and Professor of Molecular Genetics, Biochemistry, and Pediatrics at the University of Cincinnati College of Medicine, Cincinnati, Ohio. He has authored more than 290 scientific publications and is a regular reviewer of 10 different medical journals. In addition to his extensive clinical experience, Dr. Grabowski’s research interests include lysosomal storage diseases and enzyme replacement therapies. His research, particularly in lysosomal storage diseases, has been funded by the National Institutes of Health for the past 25 years. Dr. Grabowski received his B.A. from the University of Minnesota and his M.D. from the University of Minnesota Medical School.

If you liked this article you might like

The Nominees for Best Biopharma CEO of 2015 Are...

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

New Lifetime High Today: Synageva BioPharma (GEVA)

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years